Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds (AIM-2)

A

Air Force Military Medical University of People's Liberation Army

Status

Enrolling

Conditions

Ischemic Stroke

Treatments

Drug: Antithrombotic drugs

Study type

Observational

Funder types

Other

Identifiers

NCT05032053
XJLL-KY20212114

Details and patient eligibility

About

To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.

Full description

Cerebral microbleeds (CMBs) are caused by microvascular lesions in the brain, which is a subclinical deposition of hemosiderin after the damage of microvascular. Antithrombotic drug are widely used in the secondary prevention of patients with ischemic stroke. Studies have shown that antithrombotic drug can increase the incidence of intracranial hemorrhage in ischemic stroke patients with cerebral microbleeds. For such patients, how to carry out effective and safe antithrombotic therapy is still unclear. We will study from two aspects: 1) We designed a cohort registration study to observe the prognosis and progress of CMBs in ischemic stroke patients one year after using various antithrombotic drugs. 2) Data independent acquisition quantitative proteomics (DIA quantitative proteomics) will be used to screen serum protein markers that may affect the prognosis of ischemic stroke patients with CMBs.

Enrollment

3,000 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed clinically as ischemic stroke;
  • Age ≥ 40 years;
  • Onset time ≤ 3 months;
  • Informed consent was signed.

Exclusion criteria

  • Patients with symptomatic intracranial hemorrhage;
  • bleeding lesion > 10 mm was found on SWI;
  • Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;
  • There are contraindications for antithrombotic drugs use;
  • Serious systemic diseases;
  • Refusal to sign informed consent or poor compliance.

Trial contacts and locations

0

Loading...

Central trial contact

Fang Yang, Ph.D; Wen Jiang, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems